drugset / Trial / NCT01228513

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

NCT01228513

Phase 2 Completed 263 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.

Timeline

Start
2010-11
Primary completion
2011-07
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mapracorat Small molecule 0.01 % Topical
Comparator Mapracorat Small molecule 0.03 % Topical
Comparator Mapracorat Small molecule 0.1 % Topical

Indications